Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Sept. 03, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Outset Medical, Inc. ("Outset" or the "Company") (NASDAQ:OM) investors of a class action representing investors that bought securities between Aug. 1, 2022 and Aug. 7, 2024, inclusive (the "Class Period"). Outset investors have until Oct. 28, 2024 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, ...

Core Viewpoint - A class action lawsuit has been filed against Outset Medical, Inc. for alleged violations of securities laws, specifically related to misleading statements about its Tablo products [1][4]. Group 1: Lawsuit Details - The lawsuit is based on claims that Outset made false and misleading statements regarding its Tablo products, which were marketed for continuous renal replacement therapy without FDA approval [4]. - The class period for the lawsuit is defined as from August 1, 2022, to August 7, 2024, during which investors are encouraged to participate if they suffered losses [2]. - The Schall Law Firm is representing investors and has not yet certified the class, meaning potential participants are not currently represented by an attorney [3]. Group 2: Company Operations - Outset is expected to submit a 510(k) application to the FDA for its Tablo products, but sales are likely to be halted until this application is approved [4]. - The company reportedly lacks the sales force necessary to effectively ramp up sales of the Tablo products, contributing to the misleading nature of its public statements [4]. - The revelation of the truth about Outset's operations has led to investor damages, indicating a significant impact on the company's market perception [4].

Core Viewpoint - A class action lawsuit has been filed against Outset Medical, Inc. for alleged violations of federal securities laws related to misleading statements about the company's products and operations [1][2][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased Outset Medical securities between August 1, 2022, and August 7, 2024 [2]. - Allegations include that Outset Medical made materially false statements regarding the Tablo products, including marketing for unapproved uses and lacking the necessary sales infrastructure [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Outset Medical have until October 28, 2024, to request to be appointed as lead plaintiff in the case [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - The law firm operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. - Bronstein, Gewirtz & Grossman, LLC has a history of recovering significant amounts for investors in securities fraud cases [6].

SAN FRANCISCO, Aug. 31, 2024 (GLOBE NEWSWIRE) -- Hagens Berman Outset Medical (NASDAQ: OM) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may assist the investigation to contact its attorneys. Class Period: Aug. 1, 2022 – Aug. 7, 2024 Lead Plaintiff Deadline: Oct. 28, 2024 Visit: www.hbsslaw.com/investor-fraud/om Contact the Firm Now: OM@hbsslaw.com 844-916-0895 Outset Medical, Inc. (OM) Securities Class Action: The litigation focuses ...

NEW YORK, Aug. 31, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Outset Medical, Inc. (NASDAQ: OM) between August 1, 2022 and August 7, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 28, 2024. So What: If you purchased Outset Medical securities during the Class P ...

NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Outset Medical, Inc. ("Outset Medical" or the "Company") (NASDAQ: OM) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Outset Medical securities between August 1, 2022 and August 7, 2024, both dates inclusive (the "Class Per ...

NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Outset Medical, Inc. ("Outset Medical" or the "Company") (NYSE: OM) securities between August 1, 2022 and August 7, 2024, inclusive (the "Class Period"). The lawsuit seeks to recover damages for the Company's investors under the ...

ATLANTA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Outset Medical, Inc. ("Outset Medical" or "the Company") (NASDAQ: OM). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company's business, operations, and prospects, including allegations that: (1) the Tablo products were marketed for continuous renal replacement therapy, which is not one of the indications appr ...

SAN DIEGO, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Outset Medical, Inc. (NASDAQ: OM) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws. What if I purchased Outset Medical securities? If you purchased securities and suffered ...

NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Outset Medical, Inc. ("Outset" or the "Company") (NASDAQ: OM) on behalf of Outset stockholders. Our investigation concerns whether Outset has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. The investigation focuses on whether the Company issued false and/or mi ...